SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " harm " 2,190 found 🔀 AI-powered Shuffle
Xbox leader Asha Sharma says there's "more demand than consoles available" as Xbox hardware sales dip by 14%
There's apparently more demand for Xbox consoles than there is supply, according to Microsoft, and it's working on a refurbishment programme to address this.
Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2026 Financial Results
CAMBRIDGE, England & BOSTON, October 29, 2026--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate updates.
Do You Still Need Your Antidepressant? What to Know Before You Stop
Do you have to take antidepressants forever? The answer isn’t the same for everyone, explains psychiatric medication expert Jane Sundberg, PharmD, BCPP of University of Rochester Medicine.
Health Care Trade Groups Leaning Right
Yet, the most recent filings by the political action committees of the American Hospital Association, AHIP (America’s Health Insurance Plans), the Pharmaceutical Research and Manufacturers Association and the American Medical Association reveal the industry is continuing to provide financial support for Republican incumbents. They are still funding the party that’s kicking them in the teeth.
Global Health & WASH
The US National Institutes of Health reopened its center and program-project machinery in force. NIGMS is funding Collaborative Program Grants for interdisciplinary teams, NIAID opened both its Immune Tolerance Network and a next-generation R&D call, the NCI runs its Carcinogen Hazard Assessment Monographs program, the National Library of Medicine is funding institutional training in biomedical AI and data science, and NIH reopened its Centers for AIDS Research. The tell: these pay for standing centers and multi-year consortia at institutions with an existing funded research base, not one-off projects, so the fit is an established US research institution, not a single investigator. Disease-specific foundations are again funding the researcher, not just the research. The Parkinson’s Foundation opened its Paul Oreffice Innovations in Care Award and the National Ataxia Foundation its Research Seed Money Grant. The tell, the same one we flagged last cycle, is a named early-career or seed award that builds a pipeline of scientists committed to one condition, so what wins is a researcher willing to specialize. The post-USAID global-health money is routing through a State Department program statement and multilateral innovation funds. The US Department of State’s Bureau of Global Health Security and Diplomacy opened its Advancing Global Health Annual Program Statement, Grand Challenges Canada opened Nexa Lighthouse for climate and health innovation in Asia and the Pacific at USD $250,000 to $2,000,000, and CEPI opened a rolling call on vaccine-manufacturing analytics. The tell: the largest health money this cycle sits in a standing program statement and in staged innovation vehicles, not in a single bilateral grant. Total Estimated Funding Pool: ~$35.4M across discrete grants. (Separately, large national-formula envelopes not counted in this total: U.S. Department of State, Bureau of Global Health Security and Diplomacy (GHSD).) This post is for paid subscribers. This helps support the time and effort it takes to curate and organize these opportunities. Subscribe To keep this accessible to everyone who needs it, we’re happy to offer pay what you can rates. You can find more details here. New opportunities: Paul Oreffice Innovations in Care Award, Parkinson’s Foundation. *New!* *Closing soon!* The Parkinson’s Foundation created the Paul Oreffice Innovations in Care Award to fund clinicians rethinking how people with Parkinson’s disease receive care. The Foundation is using pilot funding to move promising ideas into testable projects, backing work across four lanes: strengthening community clinician capability, redesigning care models, building patient-centered technologies, and defining the minimum clinical datasets that make better standards possible. It wants hypothesis-driven, clinically grounded projects that can generate evidence strong enough to attract further funding. By opening the door to clinicians at every career stage and strongly preferring projects that involve people with Parkinson’s in their design, the Foundation signals that it values practical, patient-shaped innovation over prestige. The strongest fits are US-licensed clinicians with a focus on Parkinson’s and an institutional home for applied care research. Geographies: united states. Who can apply: Clinicians of all career stages, from fellows to established faculty, who are licensed to care for patients in the United States and have a significant focus on Parkinson’s disease. Physicians must have completed a neurology residency (or justify how their training pathway benefits people with PD); allied health professionals must hold an advanced degree, typically a PhD. Fellows, those in mentored positions, and those within two years of starting an independent position require a mentor and a mentor support letter. The sponsoring institution’s grants office is the authorized recipient and funds are disbursed to the institution. Funding amount: Maximum of $200,000 over two years; up to three awards. Targeted Sectors / SDGs: Health; Innovation; Science & Technology. Deadline: November 1, 2026. Learn more and apply here. Design and Deliver the Next EIT Health Bootcamps, EIT Health. *New!* *Closing soon!* EIT Health is opening its call for consortia to design and deliver the next generation of its health start-up bootcamps, funding the curriculum, masterclasses, mentoring, and investor engagement that turn early health ventures into fundable companies. The organization is using these learning paths to strengthen Europe’s health innovation pipeline across digital health evidence, deep tech and AI commercialization, cross-border investment, and patient access. What EIT Health wants to back is not a single course but durable delivery capacity built by partners who span industry, education, and research. Requiring multi-country consortia and a revenue-sharing stake in the programs signals that EIT Health expects these bootcamps to outlast the grant. The strongest fits are established training providers, universities, and industry partners with proven reach into health entrepreneurs. Geographies: Europe. Who can apply: Consortia only (individuals cannot apply), comprising a minimum of two and a maximum of five independent legal entities. Partners must cover at least two sides of the Knowledge Triangle (industry, education, research), including at least one industry organisation, and at least two entities must be legally established in different Horizon Europe countries. Funding amount: Foundational Learning Path: up to EUR €112,000; Thematic Learning Paths: up to EUR €124,500 per path (up to four thematic projects); up to EUR €610,000 total EIT Health funding available under the call. Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. Technology Transfer Offices & Entrepreneurship Support Call (Beyond the Lab: From Research to Venture), EIT Health. *New!* *Closing soon!* EIT Health is opening its Technology Transfer Offices and Entrepreneurship Support Call to fund consortia that will deliver the Beyond the Lab: From Research to Venture program for healthcare researchers. EIT Health is using the grant to build local capacity for turning laboratory science into incorporated start-ups, paying experienced technology transfer offices and entrepreneurship support providers to run masterclasses, structured mentoring, and a closing Pitch Day across two cohorts. It wants to back organizations that can walk researchers from discovery to company formation, not just teach theory. Requiring two transfer offices plus one venture-building provider signals that EIT Health values proven commercialization experience alongside academic reach. The strongest fits are European research-commercialization teams with a track record of moving health innovations toward investable ventures. Geographies: Europe. Who can apply: A consortium of two Technology Transfer Offices (representing higher education institutions or research organisations) and one Entrepreneurship Support Provider with demonstrated experience in venture building and start-up support. Applicants may apply for more than one learning path where they can demonstrate the required expertise and capacity for each. Funding amount: Up to EUR €77,000 in 2027 and up to EUR €77,000 in 2028 (up to EUR €154,000 total per consortium over two years). Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. EIT Health RIS Country Representatives Call (2027-2028), EIT Health. *New!* *Closing soon!* EIT Health is seeking organizations to serve as Country Representatives across eleven Regional Innovation Scheme countries in central and eastern Europe for the 2027 to 2028 period. The money funds a national anchor in each country, an organization that maps the local health innovation ecosystem, connects startups and researchers to EIT Health programs, and builds the stakeholder relationships that let health ventures grow. EIT Health is backing local capacity rather than individual projects, which is why it accepts both single organizations and national consortia that span education, research, and industry. The requirement for co-financing signals that it wants representatives already embedded in their national systems. The strongest fits are established ecosystem builders with deep ties to health innovation stakeholders in one eligible country. Geographies: Croatia; Czech Republic; Estonia; Greece; Hungary; Latvia; Malta; Romania; Serbia; Slovenia; Turkey. Who can apply: Registered legal entities established in one of the eligible EIT RIS countries. Single organisations or national consortia may apply. Consortia must include at least two sides of the Knowledge Triangle (education, research and industry), and all consortium partners must be established in the same eligible country. Suitable applicants have demonstrated experience in healthcare innovation ecosystem development, innovation support and entrepreneurship, start-up acceleration, technology transfer, research and higher education, business support, and stakeholder engagement, with strong links to national innovation stakeholders. Funding amount: Up to EUR €182,000 per Country Representative (maximum funding per project); total call budget up to EUR €1,274,500; EIT Health funds up to 60% of total eligible project costs. Targeted Sectors / SDGs: Health; Innovation; Science & Technology; Economic Development & Livelihoods. Deadline: November 2, 2026. Learn more and apply here. Architects of Trust: Community-Driven Demand Creation for New TB Vaccines, Treatment Action Group (TAG). *New!* *Closing soon!* Treatment Action Group, with funding from Wellcome, is opening its Architects of Trust call to help communities prepare for the new tuberculosis vaccines now moving through late-stage trials. The money backs civil society and community-based organizations to raise awareness, surface local questions and concerns, and press policymakers toward equitable national rollout. By pairing each grantee with an advocacy mentor and running a strategy workshop alongside the Global TB Vaccine Forum, Treatment Action Group is building a durable advocacy bench rather than funding one-off outreach. The two-stage design, starting with a short expression of interest, signals that fit and community rootedness matter more than polished proposals. The strongest fits are locally trusted groups with real TB, immunization, or health advocacy experience and a committed project lead. Geographies: Brazil; Ethiopia; India; Indonesia; Kenya; Malawi; Mozambique; Nigeria; Peru; Philippines; South Africa; Tanzania; Vietnam; Zambia. Who can apply: National, subnational, or regional civil society organizations (CSOs) or community-based organizations based in one of the 14 eligible countries or in Eastern Europe/Central Asia regional networks, with experience in TB, immunization, or other health advocacy and in community engagement or policy advocacy; well integrated into stakeholder networks with membership or affiliation to other CSO or community networks; naming a dedicated project lead (’architect of trust’) who can attend the April 2027 Zaragoza forum in person; and holding (or committing to adopt) organizational policies on safeguarding (bullying, harassment, abuse, and harm), equity, diversity and inclusion, and legal compliance, research practice and governance. Funding amount: Grants of up to US$45,000 will be awarded to 8 CSO partners across 14 high-TB-burden countries plus regional networks in Eastern Europe and Central Asia; each grant funds 12 months of work. Targeted Sectors / SDGs: Health; Governance; Policy & Advocacy. Deadline: November 4, 2026. Learn more and apply here.
Trump administration will allow pharmacies to make popular peptides
The Department of Health and Human Services will let small compounding pharmacies make six peptides that haven't been approved by the Food and Drug Administration. It may not be enough to meet demand.
Health Secretary Kennedy opens access to some unapproved peptides
Robert F. Kennedy Jr. on Wednesday pushed forward a policy allowing licensed pharmacies and physicians to compound certain unapproved peptides.
General Lost Profits Analysis Versus Insured Business Interruption Loss Analysis
Forensic accountants often perform similar analyses for lost profits and business interruption claims, but while lost profits analysis aims to measure total economic harm from wrongful conduct, business interruption analysis determines recoverable losses under specific insurance policy terms—often resulting in different damage amounts due to coverage limitations, waiting periods, and restoration period restrictions.
Climate change intensifies global health risks, Lancet Countdown report warns
The 2026 Report of the Lancet Countdown on Health and Climate Change finds that many of the health risks and harms of climate change grew faster in the decade since the Paris Agreement was introduced (2016–2025) than in the decade before it (2006–2015).
Climate change should be declared global health emergency, experts say
Climate change should formally be declared a global health emergency, experts have warned after they found that impacts on human health are outpacing the action countries are taking. Health harms from...
Climate change is a 'global health emergency' and the harms are accelerating, Lancet report warns
Many detrimental health indicators linked to climate change are moving in the wrong direction, the report's authors said.
The Cost of Lagging Global Climate Action Is Lost Lives and Poor Health
A new report finds health harms from warming outpaced progress after the Paris Agreement and calls for climate change to be declared a global health emergency.
Anthropic's 97-page list of business risks is quadruple the length of other AI IPOs. What's on it: weapons, blackmail, and more
Anthropic warns potential investors its agents could do serious harm, both autonomously and in the hands of malicious actors.
Republicans laud feds for awarding Florida $193.7M for rural healthcare
Florida has been awarded $193.7 million in federal funds to support telemedicine, remote patient monitoring, pharmacy services, diagnostic kiosks, and community paramedicine for rural areas in Florida, the Centers for Medicare and Medicaid Services announced. The grant is $5 million-plus more than the DeSantis administration had previously announced it was requesting. The money is made […]
Jazz Philharmonic to honor Davis 100th
The Chicago Jazz Philharmonic continues its Miles Davis centennial celebration with an extraordinary two-act performance: “Miles Davis at 100: Kind of Blue” and “Sketches of Spain: Revisited” on Saturday, Nov.
Long-Term Health Effects of Chemical Leak
UToledo Health pulmonologist Dr. Fadi Safi explains that a harmful chemical’s health effects depend not just on how long a person was exposed, but also on its concentration.
Opinion: As Illinois patients struggle to afford care, hospitals profit
A little-known program allows hospitals to purchase drugs for as little as a penny and then resell them for thousands, inflating Illinoisans’ pharmacy bills and insurance premiums.
State Health Plan update: Atrium back in network for state workers
Atrium, the state’s biggest hospital chain, has agreed to end a pricing plan that state officials said would harm the financial health of the State Health Plan. In return, the State Health Plan has agreed to put Atrium back in network.
Global framework urgently needed to assess emerging health risks of novel chemicals, experts say
Over the past century, humanity has invented a dizzying array of novel chemicals for industrial, commercial and domestic use. These synthetic chemicals have been manufactured and released into the world with little caution for the harm they might cause to human health or to ecosystems that we depend on for life as we know it. […]
India's MedPlus Health posts higher Q2 profit as retail revenue rises
Oct 27 () - Indian pharmacy chain MedPlus Health Services reported a slight increase in second-quarter profit on Tuesday, helped by higher demand at its retail unit and store network expansion. Here are some more details: • The company reported a consolidated net profit of 560.
How a Florida State University researcher uses AI to track hidden health risks from red tide
Red tide, a harmful algal bloom that produces toxins, is known for causing respiratory irritation in humans and killing fish in coastal waters. Recent
The Texas trans advocacy texts and mailers were fake. Their impact is real, and hard to control
Texts and pamphlets purportedly sent out by a Texas transgender advocacy group were soon debunked as fake. But the scheme highlights how hard it can be to stem the flow of incessant political marketing during election season — and to reverse its harmful effects.
The fight to save Jodrell Bank Observatory
Pulling funding from world’s third largest telescope is ‘act of national self-harm’, with planned cuts ‘just the tip of the iceberg’, say scientists
Abhishek hits 35-ball ton as India hammer New Zealand
Abhishek Sharma's 113 from 38 balls helps India chase a target of 199 in just 13.2 overs against New Zealand.
Risks spelled out for Anthropic investors include possible harms from runaway AI
Any time a company looks to start selling shares on Wall Street, it’s required to disclose potential risks for investors.
Pumpkins with Purpose brighten Palm Beach for a cause
There were pumpkins, philanthropy and plenty of Palm Beach charm for four festive days as Cancer Alliance of Help & Hope and The Royal Poinciana Plaza celebrated the ninth annual
MU Health Care to buy Summit Pharmacy in Holts Summit
The health system has signed an agreement to purchase Summit Pharmacy at 140 Northstar Drive, with the transaction expected to be finalized in December.
Classic Rock Orchestra Will Present Anthems Of ‘70s, '80s
Nineteen musicians from the Plymouth Philharmonic Orchestra will join singer and multi-instrumentalist Joe Boucher and Classic Rock Orchestra on stage for “Anthems of the ’70s and ’80s” on Thursday, November
In brief: Orlando Bloom, Elijah Wood joining 'The Gentlemen'
Netflix is rounding up more gentlemen. Tudum announced Orlando Bloom, Elijah Wood and Ed Speelers are joining stars Theo James and Kaya Scodelario for the third season of The Gentlemen, which is currently filming in the U.K. and Morocco. Also added to the series cast are Dexter Fletcher, Robert Carlyle and Bugzy Malone, who appeared in the 2019 film that inspired the Netflix series. Daniel Ings, who played the drug-addled older brother Lord Frederick “Freddy” Horniman to James’ criminal mastermind Eddie Horiman, told HATC magazine he will not return for the third season. Netflix has not confirmed this …The action-adventure series Fallout has inspired a new reality show. Prime Video has revealed Fallout Shelter: The Experiment, an unscripted competition inspired by the post-apocalyptic drama series and the video game universe. The show “invites everyday participants to test their aptitude for the apocalypse in Vault-Tec's state-of-the-art bomb-proof vault shelters," according to Prime Video. Contestants will “go head to head in a series of high-octane drills, psychological dilemmas and morally challenging behavior trials.” The winner walks away with a $1 million prize. Fallout Shelter: The Experiment will begin streaming in January 2027 … TNCMS.AdManager.render({region: 'fixed-big-ad-top-asset', slot: 1, fold: "above"}); Bravo renewed a slate of its reality shows ahead of Bravo’s Fan Fest on Saturday. New York-based In the City has been greenlit for season 2, while Next Gen NYC is coming back for a third season. For viewers seeking a little Southern charm, The Next Gen universe will be expanding with a spinoff based in Atlanta, and Southern Hospitality is moving forward with a fifth season. Premiere dates have not yet been announced … Copyright © 2026, ABC Audio. All rights reserved. Thank you for reading kmaland.comAt KMA, we attempt to be accurate in our reporting. If you see a typo or mistake in a story, please contact us by emailing kmaradio@kmaland.com.
Il Volo celebrates nearly 20 years of musical harmony
Longer than many marriages and most rock bands, the Italian singing trio Il Volo have been together for almost 20 years. They’ve gone from teenagers to 30-somethings while selling more
Johnson & Johnson Deepens Hong Kong Commitment with Strategic Partnership to Accelerate Healthcare Innovation
Johnson & Johnson Deepens Hong Kong Commitment with Strategic Partnership to Accelerate Healthcare Innovation
12 Fun USB-C Gadgets For Your Home Office Desk
Some fun USB-C desk gadgets include the Dockcase Explorer Smart USB-C Hub, Raspberry Pi 500, Creative Pebble SE, Kodak Charmera, and the Divoom Ditoo Pro.
Novant Health hosting Hilton Head hiring event Oct. 28
Novant Health will host a healthcare hiring event Oct. 28 on Hilton Head Island for nursing, laboratory, pharmacy and other positions.
Editorial: Company mergers are causing more harm to the entertainment industry than good
Two weeks ago, Paramount officially completed its $110 billion purchase of the historic Warner Bros.
ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
Roche has shed more light on its investigational KRAS G12C inhibitor's phase 3 victory over Amgen’s Lumakras and Bristol Myers Squibb’s Krazati. The open-label Krascendo 1 trial enrolled 338 people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC). Patients who had already received a KRAS G12C inhibitor or pan-KRAS/RAS inhibitor were excluded from the trial. Participants received either divarasib once daily, Lumakras once daily or Krazati twice daily. Roche announced back in July that divarasib had demonstrated statistically significant improvements in progression-free survival (PFS) and overall survival (OS), meeting the trial’s primary and key secondary endpoints. But the Swiss pharma had been holding back the detailed data until now. At the European Society for Medical Oncology (ESMO) Congress in Madrid, Roche revealed that median OS for the 167 patients who received divarasib was 17.7 months, compared to 12 months for the 171 patients who received Lumakras or Krazati. The benefit was similarly clear when it came to median PFS, which stood at 9.8 months versus 5.7 months, respectively. A total of 44% of patients receiving divarasib were alive without disease progression at one year, compared to 24% of the control group, according to Roche’s presentation. It was a similar story for the objective response rate, which came in at 58% for divarasib versus 32% for the control group, while median duration of response was 11.9 months versus 6.9 months. Stefan Frings, M.D., Ph.D., deputy chief medical officer at Roche Pharma, told Fierce that the data made for a “very comprehensive, strong package, which should be convincing to health authorities.” “It’s an important advance for patients with lung cancer,” Frings said in an interview at a Madrid hotel during the conference. “It's a second-line setting, and patients who receive divarasib benefit compared to the current first-generation KRAS G12C inhibitors by having far longer overall survival,” he continued. “They live longer. They have better progression-free survival, better response rates, and with a safety profile which is—if [anything]—even better,” he said. According to Roche, 4.8% of patients receiving divarasib discontinued treatment due to treatment-related adverse events, compared to 11.7% in the control group. Serious treatment-related adverse events were also less common with divarasib, at 7.8% versus 15.2%. Roche’s confidence in divarasib had been building even before this phase 3 success. The candidate had already shown better potency and selectivity than the incumbent KRAS G12C inhibitors Krazati and Lumakras in preclinical tests. After cross-trial comparisons suggested that the edge translated into better clinical outcomes, Roche axed a study comparing divarasib to the chemotherapy docetaxel and went toe-to-toe with Lumakras and Krazati. “We designed the drug on purpose with higher potency and better selectivity,” Frings explained. “So, based on preclinical models, we clearly knew it would be superior to the first generation.” “It’s honestly not so frequent that pharma companies go head-to-head,” he added. “But if you want to make a point, if you want to convince payers, prescribers and patients … then a head-to-head win is rather rewarding.” While Amgen and BMS reached the regulatory finish line first for KRAS G12C-mutated, locally advanced or metastatic NSCLC in 2021 and 2022, respectively, they have struggled to capitalize on their head start. Krazati brought in $55 million for BMS in the second quarter, while Lumakras delivered $111 million to Amgen. For its part, Roche is aiming for peak divarasib sales of 1 billion to 2 billion Swiss francs ($1.2 billion to $2.5 billion), according to Frings. The Big Pharma is currently recruiting patients into a phase 3 trial comparing divarasib plus Keytruda against Keytruda plus chemotherapy in previously untreated advanced or metastatic nonsquamous KRAS G12C-mutated NSCLC. Roche has previously suggested that sales in metastatic disease would account for most of the forecast. Frings was tight-lipped on the exact timeline for a regulatory filing but said the Swiss pharma is “certainly keen to get this to as many patients as possible around the world.” Roche has more RAS drugs coming up behind divarasib. The pharma has already launched phase 1 trials of a pan-RAS inhibitor called RG6505 and a KRAS G12D inhibitor dubbed RG6620 in solid tumors. Roche’s partner Chugai Pharmaceutical is also testing a pan-KRAS inhibitor called AUBE00. Roche has made a “deliberate effort” to test a range of RAS drugs, Frings said. “If you have many rare mutations and you are scrambling to find sufficient patients, a pan-RAS inhibitor makes a lot of sense,” he explained.
Instacart Stock What Health Benefits Deal And $5 Million Settlement Mean
Instacart parent Maplebear has agreed to a US$5,000,000 settlement with U.S. authorities over past PERM hiring practices and has been selected by True Rx Health Strategists to power an employer funded healthy food benefit through Instacart Health Fresh Funds starting in 2027. The True Rx program positions Instacart within pharmacy benefit design and ties employer spend directly to clinically supervised food choices. The settlement adds compliance obligations, policy changes and monitoring...
Just two drinks a day may be far riskier than you think
A major new study reveals that drinking just two alcoholic beverages a day is associated with a 1 in 25 lifetime risk of death from alcohol-related causes, challenging the idea that moderate drinking is harmless. Researchers also found no significant overall health benefits from alcohol, with risks rising as consumption increases.
Just two drinks a day may be far riskier than you think
A major new study reveals that drinking just two alcoholic beverages a day is associated with a 1 in 25 lifetime risk of death from alcohol-related causes, challenging the idea that moderate drinking is harmless. Researchers also found no significant overall health benefits from alcohol, with risks rising as consumption increases.
Reducing drug harm in NC mountain counties
Needle exchanges, disease testing, providing Narcan and other harm reduction efforts navigate complexities of Western NC communities.
Xbox Reportedly Bungled $500 Million Netflix Deal
According to industry insiders, newly appointed Xbox CEO Asha Sharma overplayed cross-media potential with recent Netflix exec Peter Rice to the tune of $800 million
Xbox's first chief operating officer Helen Chiang leaves Microsoft just three months into the job
Helen Chiang is leaving Microsoft just three months after becoming Xbox's first chief operating officer, according to a memo from CEO Asha Sharma.
Ramstad: Minnesota’s new leaders must face if high taxes harm growth
Minnesota has the nation’s second-highest business tax rate, following only New Jersey. But it will be No. 1 in 2029 if there’s no change.
Child-led citizen science helps Ecuadorian community tackle beach pollution and shape environmental decisions
Pollution from human-generated waste in marine ecosystems has reached critical levels, with cigarette butts (CBs) among the most persistent and harmful pollutants. Globally, an estimated 4.5 trillion ...
CVS is trying out pharmacists in chronic health management
Dr. Amy Compton-Phillips on Friday said healthcare affordability and access could potentially improve if pharmacists in its 9,000 retail stores play a bigger role in chronic disease management.
Health Brief: Making sense of Treasury’s biotech deal proposal
Pharma sees a potential catch in Washington’s latest effort to curb China’s biotech ambitions
Xbox's First-Ever Chief Operating Officer Leaves Role Just Three Months After It Was Created
Helen Chiang, Xbox’s first-ever chief operating officer, has abdicated the role just three months after it was created, as told by CEO Asha Sharma in an internal memo today.
Cone Health plans to buy 3 Reidsville pharmacies
Cone Health's plans are part of a growing trend of consolidation in health care. An economist explains what that could mean for patients and prescription prices.
Netflix reportedly offered Microsoft $500 million to license Xbox games for adaptations.
Xbox CEO Asha Sharma and team countered by asking for $800 million, and Netflix has pulled its offer, Puck reports in an article discussing the new leadership at Netflix. Xbox launched an “XP” division this month that will work on adaptations of its games, and Xbox is already working with Netflix on a Diablo animated series. [Link: The Peter Rice Playbook & Elon's Skydance Motive | https://puck.news/newsletter_content/what-im-hearing-the-peter-rice-playbook-elons-skydance-motive/ | Puck]
NYC Health + Hospitals/Bellevue Earns Eight-Year National Accreditation for Pharmacy Residency Program
NYC Health + Hospitals/Bellevue today announced that its Postgraduate Year One Pharmacy Residency Program has received an eight-year accreditation from
Senator says planned Meta commercial terms update could harm US businesses
WASHINGTON, Oct 23 (Reuters) - US Senator Marsha Blackburn, a Tennessee Republican, on Friday raised concerns about Facebook parent Meta Platforms' plan to update its commercial terms, saying it coul...
Progressive Community Health Centers expands services with new pharmacy
Looking to fill a void in pharmacy access on Milwaukee’s north side, Progressive Community Health Centers will open a full-service retail pharmacy Monday
Rural Health Care: A Look at Priorities and the Pharmacy Professional's Role
Understanding local health care priorities is essential to developing meaningful solutions.
Essential Health highlights personalized direct primary care in Davenport
Essential Health Direct Primary Care offers pediatric and adult patients personalized, evidence‑based care through a flat‑rate membership model that includes extended visits, in‑house pharmacy services and on‑site lab testing.
Treat Pandemic Preparedness As Strategic ‘Biodefence’, Industry And Health Leaders Urge
Speaking at a flagship World Health Summit panel global health officials and pharmaceutical executives urged governments to reframe pandemic preparedness as ‘biodefence’ - a core national security asset and not a discretionary health expenditure.
FDA Should Practice the Science It Preaches
The FDA has plenty of advice for pharmaceutical companies. It publishes guidance documents, establishes scientific expectations, and expects drug developers to explain themselves when they take a diff...
Moderna Named a Top Employer by Science for Twelfth Consecutive Year
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and
You Are What You Eat: An Alternative to MAHA for Healthy Food and Fewer Chemicals
CAP’s science-based plan would remove corporate and political influence from regulatory agencies, guarantee food safety, protect Americans from harmful chemicals in everyday products, and empower families to make healthy choices.
FDA Should Practice the Science It Preaches
The FDA has plenty of advice for pharmaceutical companies. It publishes guidance documents, establishes scientific expectations, and expects drug developers to explain themselves when they take a diff
Il Volo celebrates nearly 20 years of musical harmony
Longer than many marriages and most rock bands, the Italian singing trio Il Volo have been together for almost 20 years. They’ve gone from teenagers to 30-somethings while selling more
I thought I was dying but it was health anxiety - here's how to recognise the signs
Hollie Sharman shares her experience of health anxiety and a doctor advises on how to manage symptoms.
Dealroom.co | Life Science Connect buys PharmaSource and CDMO Live from Life Science Networks
What's the deal? In June 2026, Life Science Connect, the US-base…
Cone Health to acquire three Reidsville pharmacies
Cone Health is acquiring three pharmacies in Reidsville with the hopes of expanding affordable access, onsite vaccinations and continuing community-based care.
Dementia risk may be linked to seemingly harmless daily habit, new research suggests
Even naps under 30 minutes raised dementia risk 40% in a Johns Hopkins Bloomberg School of Public Health study of nearly 1,000 older adults.
Healthcare shouldn’t be so hard; health literacy can help
OPINION — A visit to the doctor may get you a diagnosis. A trip to the pharmacist fills the needed prescription. Your health plan has all sorts of information about benefits. Healthcare. Straightforward and easy to understand, right? Eye roll. Laugh stifled.
Kettering Health Pharmacist Receives Ohio Resident of the Year Honor
Just months after returning to Kettering Health as a clinical oncology pharmacist, Annie Weckesser has received one of Ohio's top honors for pharmacy residents.
Public health programs can ‘rewire’ social networks, Yale study finds
A maternal and child health education program implemented in rural villages in Honduras changed the communities’ social networks in ways that could be harmful or beneficial.
Introspection required if EU Inc fails, says start-up lobbyist
European start-ups have a new voice in Brussels. Startups for Europe, created from the merger of lobby groups Allied for Startups and the European Startup Network, is hoping to harness the momentum behind EU-Inc, a campaign that united start-ups and investors behind demands for a new pan-European company regime.At a launch event for the new association in Brussels on October 1, the mood was remarkably upbeat compared to a typical Eurobubble gathering, more Silicon Valley than Schuman roundabout.When asked whether this reflects a feeling that Europe is on the right track, chief executive Serena Borbotti-Frison said it’s a “scary” moment as the continent looks to boost its competitiveness amid a new technological arms race.“What is at stake is quite intense, and the way we can answer is by delivering, but also with hope,” she told Science|Business. “It’s what our industry does. It’s not about identifying a pain point and then saying it’s too hard.”For many in the start-up community, that sense of hope is dwindling. In March, the European Commission presented its proposal for EU Inc, naming its initiative after the grassroots campaign.EU Inc was meant to be a gamechanger: the ability to incorporate within 48 hours for less than €100 and scale up across Europe; a harmonised stock option regime enabling start-ups to compete for talent; and simplified insolvency procedures for innovative start-ups to reduce the cost of failure.However, haggling by EU governments has raised concerns that EU Inc will be stripped of the very features, including stock option harmonisation, that are meant to make it attractive for companies.“I fear we are proving to ourselves that the model doesn’t work,” Borbotti-Frison said of the policymaking process. “Everyone agrees we should have EU Inc. Everyone agrees it’s hard to scale and we need to scale to answer the competitiveness [challenge], and still we cannot deliver? [. . .] What does that say about ourselves?”The Commission has made EU Inc a cornerstone of its single market reform, and has agreed with the European Parliament and the Council of the EU to target an agreement by the end of 2026. However, several points are currently holding up an agreement, including national rules around employee participation in management decisions, and the provision that employee stock options always be taxed at the point of sale. Some EU governments have reportedly pushed back on the Commission’s choice of legal basis, contending that anything related to taxation requires unanimity in the Council.Trade unions have also protested against EU Inc, fearing it will be exploited by companies looking to undermine workers’ rights.“If this doesn’t work, it’s introspection time, on the way our institutions work, maybe the way our lobbies work, and maybe the way the cooperation between them works,” Borbotti-Frison said.“Is it in the national interest? Is it a gap between political will and technical ability to operate? Is it speed? I don't know, but something needs to be fixed.”Ahead of last week’s European Council meeting, EU-Inc campaigners tried a new strategy: appealing directly to EU presidents and prime ministers. In an open letter, they urged EU leaders to “step in and give your negotiating teams a clear mandate to change course and reverse their objections to the Commission’s original proposal.”Lessons from EU-IncLike its predecessors, Startups for Europe will represent national start-up associations, but it is also targeting investors. The founding sponsors are venture capital firm Atomico and EQT, the investor selected earlier this year to manage the €5 billion Scaleup Europe Fund.It also wants to harness the knowledge and cross-border experience of European success stories. “Take the list of the 100 biggest unicorns in Europe. We are speaking to all of them,” Borbotti-Frison said. The association plans to publish a full list of supporters following the Slush tech conference in Helsinki in November.Andreas Klinger and Simon Schaefer, two key figures in the EU-Inc campaign, are both on the board of the new association, and Startups for Europe wants to take the lessons from their campaign.What was unprecedented about EU-Inc was “how rooted it was, and how strong it was in bringing everyone on board behind one clear pain point and solution to fix it,” Borbotti-Frison said. “This is an inspiration for us, and then we need to turn it into something more systematic, more bridged in Brussels, more connected to the policymaking game, and to scale it.”If it’s possible to unite such a broad coalition, it’s because the European start-up ecosystem is now mature, she said. “Maybe it was not ten years ago. Maybe it was not five years ago. But now, it’s mature to speak with one voice.”Open and liberal EuropeThe association plans to campaign on files related to three “pain points,” Borbotti-Frison said: “start and scale in Europe, fundraise and invest in Europe, and making Europe the most innovative continent.”As well as EU Inc, she cited public procurement, the EU’s simplification push, the Savings and Investments Union, and files related to AI adoption and technological sovereignty as priorities for the coming months.What these files have in common is that they relate not to subsidies but to the framework conditions influencing the availability of mostly private, or in the case of procurement, public, funding.Related articlesEmployee participation disagreement delays MEPs’ vote on EU IncCommission urges EU governments not to water down EU IncEU’s ‘ultra-fast’ €5B scale-up fund is set up to win, says its fund managerThe budget dispute over the next Horizon Europe programme will also impact start-ups, which are supported notably through the European Innovation Council. But EU innovation funding is a drop in the ocean compared to venture capital and public procurement budgets.“If competitiveness and innovation are a priority, then the [EU budget] should reflect it,” Borbotti-Frison said. However, she added that the main question is not how much public money is invested, but “how do we create the right conditions for the market to solve the problem?”The Scaleup Europe Fund mixes both approaches, using €1 billion in EU funding to crowd in private investors and address Europe’s lack of large-scale, late-stage growth funds. “It’s a proof of concept. Ideally, then the market will do it itself,” Borbotti-Frison said.Startups for Europe is also focused on bringing an alternative political narrative. Amid competing visions for open, global markets on the one side and a protectionist Europe on the other, it wants to offer “a third voice, to say we can be proudly European and build a strong continent in a liberal economy, open to the world, and global.”It can be tempting, when thinking about how Europe can better support innovation, to look across the Atlantic. But while it’s important to compare statistics to see where Europe needs to catch up, that’s where the comparison should stop, Borbotti-Frison said. “On everything else, we need to do it our own way. We don't have the same history. We don't have the same political model. We don't have the same way of life.”Many of the key files that could benefit the start-up community, including EU Inc and the Savings and Investments Union, rely on closer integration within Europe, making it easier to operate across borders.While the Commission has made deepening the single market a political priority, support at national level is more precarious. The coming months will see pivotal elections in Spain and France, while the German government has also been coming under pressure domestically. In each country, far-right parties have been gaining ground.When asked if she was concerned the political situation could jeopardise this progress, Borbotti-Frison responded: “Of course. I would be lying if I said I wasn’t.” However, she continues to believe that cooperation is the only way forward. “Doing it alone is not the solution. It’s also not who we are, it’s not the model we are building, and it’s not the scale we need.”
Britain Politics
Britain's Prime Minister Andy Burnham receives a flu vaccination from Pharmacist Aneet Kapoor in Chorlton-cum-Hardy, Manchester, England, Thursday, Oct. 22, 2026. (Christopher Furlong/Pool Photo via AP)
Britain Politics
Britain's Prime Minister Andy Burnham looks at his Manchester bee tattoo before receiving a flu vaccination from Pharmacist Aneet Kapoor in Chorlton-cum-Hardy, Manchester, England, Thursday, Oct. 22, 2026. (Christopher Furlong/Pool
Britain Politics
Britain's Prime Minister Andy Burnham meets pharmacy staff before receiving a flu vaccination at Kapoor Pharmacy Services in Chorlton-cum-Hardy, Manchester, England, Thursday, Oct. 22, 2026. (Christopher Furlong/Pool Photo via AP)
Childhood lead exposure remains a preventable health threat in the Americas
Lead exposure affects up to 815 million children worldwide. During International Lead Poisoning Prevention Week, PAHO highlights the need to identify sources of exposure, strengthen surveillance, and protect children from the harmful effects of lead.
What Pharmacists Should Know About Sea Buckthorn for Respiratory Health
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Unpacking the Public Health Turn in Internet Regulation
Measures designed to protect children from digital harms are ushering in a public health approach to internet regulation, writes Ramiro Álvarez Ugarte.
TRUE RX HEALTH STRATEGISTS BECOMES FIRST PBM TO BRING INSTACART HEALTH FRESH FUNDS TO EMPLOYER PHARMACY BENEFITS
/PRNewswire/ -- True Rx Health Strategists, the family-owned, pharmacist-led pharmacy benefit manager (PBM) based in Indiana, today announced a first-to-market...
Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027
Abbott Laboratories (NYSE:ABT) has announced plans to spin off its Nutrition division into a separate publicly traded company, with the transaction expected to be completed by the end of 2027, subject to regulatory and corporate approvals. The proposed separation would create an independent business focused on nutritional products while allowing Abbott to concentrate on its medical devices, diagnostics and established pharmaceuticals operations.
Brain fog and the FemTech market | Investors Lab
A slew of pharma heavyweights (Eli Lilly, Bayer, Pfizer, Merck, Viatris, Novo Nordisk, Roche and AbbVie) have a piece of the pie in estrogen replacement.
Taiwan Blocks Grab Acquisition of Delivery Hero Business Over Competition Concerns
Taiwan’s Fair Trade Commission said the harm of the proposed deal to the island’s food-delivery industry outweighed its overall economic benefits.
Swiss group agrees $390 million deal for medicines business with operations in North Africa
DKSH agrees to acquire NewBridge Pharmaceuticals in a $390 million deal, gaining a medicines platform with an established North African presence
Business Strategy: Re-Centering Ethics as Pharma's Competitive Advantage
By Dirk Brinckman Chief Compliance Officer, Johnson & Johnson Chair, IFPMA Ethics and Business Integrity Committee Chair, IFPMA Chief Ethics and Compliance Officers Roundtable Today is Global Ethics Day and this year’s theme is “Re-centering Ethics”. At a time when organizations face competing pressures and unprecedented change this theme serves as a call to intentionally...
How Small Pharmacy Expansion Will Impact CVS Health (CVS) Investors
CVS Health has been rolling out smaller pharmacy focused stores, expanding MinuteClinic sites and raising its 2026 revenue and earnings outlook, alongside new efforts in benefit transparency and women’s midlife health research. The push into underserved neighborhoods with compact pharmacies and clinics points to a tighter focus on access, operating efficiency and aligning physical sites with where prescription demand actually shows up. This article examines how CVS Health’s investment...
Popular supplement combinations may carry unexpected risks, health expert warns
Clinical pharmacist Jim LaValle discusses why taking excessive amounts of vitamins and minerals can pose health risks, and how identifying nutritional deficiencies can help guide safer supplementation.
Hackensack Meridian Health signs definitive agreement to acquire Hunterdon Health, commits $230M
Hackensack Meridian Health has signed a definitive agreement to pick up Central New Jersey’s Hunterdon Health, a $230 million deal that would grow the state’s largest health system to 19 total hosp | The announcement did not outline a potential timeline for the merger, which would add a nineteenth hospital to New Jersey's largest health system.
INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science
/PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and...
Xbox Game Pass Reportedly Getting 'Major Overhaul,' Will Feature 'À La Carte' Options
Microsoft is reportedly planning a substantial revamp of Xbox Game Pass that will allow subscribers to choose the features they want in an à la carte fashion. The report comes by way of a new Fortune profile piece on Xbox CEO Asha Sharma.
Trump sued over Canadian tariffs in latest legal challenge
The lawsuit argues the White House exceeded its authority in imposing the latest tariffs on the country and caused "immediate harm to American businesses".
Why child sexual abuse is our biggest public health crisis
An estimated one in five children will experience some form of sexual abuse before the age of 18. In this episode of Settle In, Amna Nawaz speaks with clinical psychologist Elizabeth Letourneau and journalist Luke Malone, authors of “One in Five,” a book that explores child sexual abuse as a public health crisis, about how education and early prevention can help protect children before harm occurs.
Harms of Public Health Measures Overlooked in COVID-19 Policy Reviews
Investigators link oversight with eroding trust in health authorities and call on future pandemic inquiries to weigh trade-offs.
The non-gamer CEO racing to save Microsoft’s Xbox
Asha Sharma has cut thousands of jobs, consolidated studios, and rewritten the playbook. Insiders wonder if she’s saving the brand or preparing it for a non-Microsoft future.
More Than Athletes: How UT Health Sciences Is Preparing the Next Generation of Sports Pharmacists
As the sports pharmacy field grows, UT Health Sciences College of Pharmacy students are learning to explore this career path.
More Than Athletes: How UT Health Sciences Is Preparing the Next Generation of Sports Pharmacists
As the sports pharmacy field grows, UT Health Sciences College of Pharmacy students are learning to explore this career path.
Evolution of women’s healthcare focus of URI’s annual Youngken Clinic
KINGSTON, R.I. — Oct. 20, 2026 — Women’s healthcare is evolving rapidly, and while greater emphasis has been placed on comprehensive care, women still face more barriers to healthcare than men, according to the National Institutes of Health. Pharmacists are key players in helping break down those barriers, playing an increasingly important role in improving […]
Life Science Connect Acquires BrevisRefero to Expand Biopharma Outsourcing Technology Capabilities
Life Science Connect (LSC) has acquired Toronto-based BrevisRefero Corporation, a biopharmaceutical consulting firm and developer of the RFP>Navigator® platform, expanding... Read More
CAS collaborates with Microsoft to enable faster innovation in pharmaceutical, life sciences, and chemical industries
/PRNewswire/ -- CAS, a division of the American Chemical Society, today announced the availability of CAS Connections in Microsoft Copilot. The connector gives...
Tecsys delivers AI capabilities to help health systems anticipate and act on pharmacy and supply chain risks
/PRNewswire/ -- Tecsys Inc. (TSX: TCS), an industry-leading supply chain management company, today announced the availability of AI solutions that help health...
Pfizer makes ‘business decision’ to end phase 2 trial of autoimmune drug as program’s future uncertain
Pfizer has called time on a phase 2 trial of its CXCR5 antibody in an autoimmune blood disorder, with the company tight-lipped on whether this marks the end of the road for the asset. The Big Pharma had been evaluating the therapy, dubbed PF-06835375, in a phase 2 study of 61 patients with primary immune thrombocytopenia (ITP) that kicked off in 2022, according to the federal trials register. However, Pfizer confirmed to Fierce on Monday that this study had been terminated “due to a business decision.” “The decision to terminate the trial was not based on any safety concerns,” a spokesperson pointed out. At time of publication, PF-06835375 remained listed on Pfizer’s website for both ITP and lupus. A phase 1 study in lupus wrapped up in 2022, according to the trials database. ITP is an autoimmune disorder characterized by a low platelet count. Novartis was at one point evaluating its B-cell-depleting antibody ianalumab—recently approved as Fabhalta to treat immunoglobulin A nephropathy—as a potential treatment ITP. But the therapy struggled to demonstrate a benefit in the clinic for this indication. When contacted by Fierce, Pfizer wouldn’t confirm whether all work on PF-06835375 has been halted, and whether the company has any other plans to explore C-X-C chemokine receptor type 5 (CXCR5) as a mechanism. CXCR5 is found in blood cancers such as diffuse large B-cell lymphoma and mantle cell lymphoma chemokine receptor. However, there is little expression in normal tissue, which has led some drug developers to explore its potential. Vincerx Pharma had at one point been planning to take an anti-CXCR5 ADC into the clinic to treat B-cell malignancies, but that ambition was scrapped due to cash constraints. Where Big Pharma is placing its bets is one of the hot topics being discussed at Fierce Biotech's high-impact event in London next month. Find out more information and register by clicking on the banner below: [ ](https://qtxasset.com/quartz/qcloud5/media/image/where_big_pharma_is_placing_its_bets.png?VersionId=B8JrRbJ.pFUSK1pJgjeWHLGm_18RdLAy)
What happened to Selena Gomez's voice? The harms of vaping, explained
Selena Gomez says vaping nicotine is what changed her voice. It can cause other serious health effects, too. Here's what to know.
Naples Comprehensive Health Collaborates with Publix Pharmacy to Launch Meds-to-Beds Service - Florida Hospital News and Healthcare Report
New service will deliver discharge prescriptions directly to patients at the hospital, helping support medication access and continuity of care October 19, 2026 – Naples Comprehensive Health (NCH) is collaborating […]
Data or privacy? Businesses can have both, MIT Sloan research finds
Data regulation doesn’t necessarily cause economic harm. Markets — and consumers — can still derive economic benefits from data collection when it’s tempered by reasonable privacy guardrails.
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative...
AI chatbots could help mental health but also reinforce harmful thinking
Artificial intelligence chatbots could help people better understand and manage their mental health, but they could also reinforce harmful thoughts and increase emotional dependence, a Curtin University ...